Sharing Insight on Myeloma, CAR T, and More in San Francisco

By
Article

We visited San Francisco, California for a State of the Science Summit on Hematologic Malignancies. The meeting covered novel agents and combinations in lymphoma, updates in acute and chronic leukemias, and modalities in the management of multiple myeloma.

We visited San Francisco, California for a State of the Science SummitTM on Hematologic Malignancies. The meeting covered novel agents and combinations in lymphoma, updates in acute and chronic leukemias, and modalities in the management of multiple myeloma.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024

Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024

Noah Stansfield
October 9th 2024
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen

IRD Gene Therapy OCU400’s Phase 1/2 Trial

Arun Upadhyay, PhD;Noah Stansfield
October 9th 2024
Article

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen, also discussed future plans for the gene therapy, which is now in a phase 3 study.

Eric Crombez, MD, the chief medical officer at Ultragenyx

In Light of Positive Initial Results, Ultragenyx Seeks to Add Higher Dose Cohort to Trial for Wilson Disease Gene Therapy UX701

Noah Stansfield
October 8th 2024
Article

Ultragenyx noted that the fourth cohort would use a “moderately increased” dose and an optimized immunodulation regimen.

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen

The Potential of Gene Therapy in Inherited Retinal Disease

Arun Upadhyay, PhD;Noah Stansfield
October 7th 2024
Article

Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen, discussed OCU400, the company’s gene-agnostic gene therapy for IRDs.

Cell Therapies Hope to be Next Frontier for Alzheimer Disease

Cell Therapies Hope to Be Next Frontier for Alzheimer Disease

Victoria Johnson
October 7th 2024
Article

As cell therapy investigations mature in the field of AD, some programs show promising signs of efficacy.

Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201

Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201

Noah Stansfield
October 6th 2024
Article

NEXICART-2 has moved on to its expansion cohort after completing dosing of patients in its initial cohort.

© 2024 MJH Life Sciences

All rights reserved.